UTHR Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 40.56% compared to United Therapeutics's net margin of 24.92%. United Therapeutics's return on equity of 19.92% beat Biomarin Pharmaceutical's return on equity of 9.62%.

United Therapeutics has a consensus price target of $388.18, signalling upside risk potential of 26.18%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $95.91 which suggests that it could grow by 66.65%. Given that Biomarin Pharmaceutical has higher upside potential than United Therapeutics, analysts believe Biomarin Pharmaceutical is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.582, which suggesting that the stock is 41.76% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.268, suggesting its less volatile than the S&P 500 by 73.157%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Biomarin Pharmaceutical quarterly revenues of $745.1M. United Therapeutics's net income of $322.2M is higher than Biomarin Pharmaceutical's net income of $185.7M. Notably, United Therapeutics's price-to-earnings ratio is 12.28x while Biomarin Pharmaceutical's PE ratio is 21.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.96x versus 3.86x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 40.56% compared to United Therapeutics's net margin of -907.48%. United Therapeutics's return on equity of 19.92% beat Moderna's return on equity of -29.23%.

United Therapeutics has a consensus price target of $388.18, signalling upside risk potential of 26.18%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Moderna has higher upside potential than United Therapeutics, analysts believe Moderna is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.582, which suggesting that the stock is 41.76% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Moderna quarterly revenues of $107M. United Therapeutics's net income of $322.2M is higher than Moderna's net income of -$971M. Notably, United Therapeutics's price-to-earnings ratio is 12.28x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.96x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 40.56% compared to United Therapeutics's net margin of -60.08%. United Therapeutics's return on equity of 19.92% beat Sarepta Therapeutics's return on equity of -20.94%.

United Therapeutics has a consensus price target of $388.18, signalling upside risk potential of 26.18%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 137.36%. Given that Sarepta Therapeutics has higher upside potential than United Therapeutics, analysts believe Sarepta Therapeutics is more attractive than United Therapeutics.

United Therapeutics has a beta of 0.582, which suggesting that the stock is 41.76% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are larger than Sarepta Therapeutics quarterly revenues of $744.9M. United Therapeutics's net income of $322.2M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, United Therapeutics's price-to-earnings ratio is 12.28x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.96x versus 1.89x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 40.56% compared to United Therapeutics's net margin of 23.33%. United Therapeutics's return on equity of 19.92% beat Vertex Pharmaceuticals's return on equity of -6.04%.

United Therapeutics has a consensus price target of $388.18, signalling upside risk potential of 26.18%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 14.71%. Given that United Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe United Therapeutics is more attractive than Vertex Pharmaceuticals.

United Therapeutics has a beta of 0.582, which suggesting that the stock is 41.76% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

United Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. United Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

United Therapeutics quarterly revenues are $794.4M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. United Therapeutics's net income of $322.2M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, United Therapeutics's price-to-earnings ratio is 12.28x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for United Therapeutics is 4.96x versus 10.17x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.